14 April 2012

TiGenix appoints Dr. Guido Schopen as vice president commercial operations.

Leuven (Belgium) – April 10, 2012 – TiGenix NV (NYSE Euronext: TIG), a leader in the field of cell therapy, today announced the appointment of Dr. Guido Schopen as vice president commercial operations. Dr. Schopen brings to TiGenix more than 20 years of bio-pharmaceutical industry experience. In addition to his global commercial responsibilities, Dr. Schopen, who is a German national, will also assume the role of country manager Germany.

“We are pleased to have attracted Guido to TiGenix,” said Eduardo Bravo, CEO of TiGenix. “He has joined the company at a pivotal time as we are building our commercial organization to capitalize on positive reimbursement decisions ahead, and are preparing to take full advantage of the end of the ATMP transition period to aggressively grow our ChondroCelect franchise. His successful track record in global marketing and sales of cutting edge biologicals and his experience in a wide range of immune mediated diseases like inflammatory bowel diseases will also prove invaluable for the launch preparation of Cx601, our lead development compound that is currently in Phase III for fistulizing Crohn´s disease.”

Dr. Schopen has joined TiGenix on April 2. Most recently he was acting as interim manager at biopharmaceutical and diagnostic companies on a number of strategic commercial programs. Prior to that he was at UCB, where as VP Global Marketing and Head of New Product Commercialization he
oversaw the development of a focused strategic direction for UCB’s immunology pipeline, as well as the successful global launch of Cimzia®, an innovative anti-TNF compound, in rheumatoid arthritis. Before that he was General Manager Immunology at UCB Germany where he set up the  Company’s new immunology business unit, built a strong network of key opinion leaders and other stakeholders, and developed a successful market access strategy.

Prior to UCB, Dr. Schopen was Director of Global Strategic Marketing at Bayer HealthCare in the US, with global responsibility for Bayer’s immunology franchise. Dr Schopen started his career in Germany holding roles in sales & marketing, business and clinical development at ICI Pharma, Hoechst/
Behringwerke AG, and Bayer AG. He earned his MD degree from the RWTH Aachen University, one of the leading academic institutions in Germany.

About TiGenix
TiGenix NV (NYSE Euronext Brussels: TIG) is a leading European cell therapy company with one marketed product for cartilage repair, ChondroCelect®, and a strong pipeline with clinical stage allogeneic adult stem cell programs for the treatment of autoimmune and inflammatory
diseases. TiGenix is based out of Leuven (Belgium) and has operations in Madrid (Spain), and Sittard- Geleen (the Netherlands). For more information please visit www.tigenix.com.

Forward-looking information
This document may contain forward-looking statements and estimates with respect to the anticipatedfuture performance of TiGenix and the market in which it operates. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”,
“anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will” and “continue” and similar expressions. They include all matters that are not historical facts. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks,
uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may depend upon factors that are beyond the Company’s control. Therefore, actual results, the financial condition, performance or achievements of
TiGenix, or industry results, may turn out to be materially different from any future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking
statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of the publication of this document. TiGenix disclaims any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in the
Company’s expectations with regard thereto, or any change in events, conditions or circumstances on which any such statement, forecast or estimate is based, except to the extent required by Belgian law.

For more information:

Eduardo Bravo
Chief Executive Officer


Claudia D’Augusta
Chief Financial Officer


Hans Herklots
Director Investor & Media Relations
+32 16 39 79 73